Compare PCRX & MHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | MHD |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 613.2M |
| IPO Year | 2011 | N/A |
| Metric | PCRX | MHD |
|---|---|---|
| Price | $26.55 | $11.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $32.86 | N/A |
| AVG Volume (30 Days) | ★ 723.2K | 124.9K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.16% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $716,791,000.00 | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $9.53 | N/A |
| P/E Ratio | $55.78 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.17 | $9.92 |
| 52 Week High | $27.64 | $12.18 |
| Indicator | PCRX | MHD |
|---|---|---|
| Relative Strength Index (RSI) | 73.51 | 46.65 |
| Support Level | $25.17 | $11.68 |
| Resistance Level | $24.81 | $11.81 |
| Average True Range (ATR) | 0.94 | 0.07 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 87.44 | 42.49 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Blackrock Muniholdings Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes. The fund mainly invests its managed assets in municipal bonds rated investment grade or, if unrated, are deemed to be of comparable quality by the investment adviser at the time of investment. Its investment portfolio is mainly comprised of long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.